{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red107\green107\blue106;
\red14\green86\blue140;
\red33\green33\blue33;
\red37\green37\blue37;
\red255\green255\blue102;
\red249\green250\blue251;
\red204\green204\blue204;
\red228\green231\blue232;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red80\green80\blue80;
\red51\green51\blue51;
\red181\green79\blue104;
\red151\green151\blue151;
\red0\green114\blue54;
\red254\green254\blue0;
\red106\green144\blue39;
\red56\green124\blue43;
\red233\green233\blue233;
\red21\green137\blue21;
\red232\green233\blue232;
\red249\green249\blue249;
\red255\green248\blue96;
\red112\green112\blue112;
\red214\green9\blue9;
\red247\green247\blue247;
\red255\green194\blue211;
\red203\green203\blue203;
\red245\green245\blue245;
\red187\green187\blue187;
\red118\green118\blue118;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red242\green242\blue242;
\red239\green122\blue2;
\red190\green190\blue252;
\red236\green236\blue236;
\red255\green255\blue204;
\red255\green204\blue0;
\red229\green243\blue255;
\red179\green218\blue255;
\red185\green185\blue185;
\red218\green218\blue218;
\red223\green223\blue223;
\red239\green239\blue239;
\red255\green255\blue198;
\red188\green41\blue30;
\red190\green237\blue228;
\red255\green255\blue174;
\red102\green0\blue102;
\red61\green61\blue61;
\red214\green214\blue214;
\red102\green102\blue102;
\red240\green248\blue255;
\red127\green127\blue127;
\red183\green242\blue206;
\red204\green255\blue255;
\red182\green231\blue243;
\red71\green120\blue194;
\red153\green255\blue102;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 Courier New;}{
\f7 serif;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj \paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cedars Sinai Medical Center v. Quest Diagnostic Incorporated, Slip Copy (2019)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
}\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_15}{\*\bkmkend co_document_15}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I789390f09f2311ea8cb395d22c142a61_Target}{\*\bkmkend I789390f09f2311ea8cb395d22c142a61_Target}
\par 
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb100 
2019 WL 8884101
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Only the Westlaw citation is currently available.
\par 
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States District Court, C.D. California.
\par 
}
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
CEDARS SINAI MEDICAL CENTER
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf22 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf22 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
QUEST DIAGNOSTIC INCORPORATED
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Case No. CV 17-5169-GW(FFMx)
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Filed 08/08/2019
\par 
}
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_15}{\*\bkmkend co_attorneysAndLawFirms_15}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0180086901&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Edward G. Poplawski
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0484499301&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lisa D. Zang
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0334898601&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Olivia M. Kim
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0500429499&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Ty William Callahan
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Wilson Sonsini Goodrich and Rosati PC, Los Angeles, CA, for Cedars Sinai Medical Center.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0216734401&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Christopher Steven Ruhland
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dechert LLP, Los Angeles, CA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0380583801&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Jonathan D. Loeb
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dechert LLP, Palo Alto, CA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0424712201&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Blake Bennet Greene
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Dechert LLP, Austin, TX, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0126764101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Diane S. Danoff
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Pro Hac Vice, Dechert LLP, Philadelphia, PA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0466300801&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Anna Quynh Do
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Dechert LLP, Los Angeles, CA, for Quest Diagnostic Incorporated.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_15}{\*\bkmkend co_opinion_15}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c2622a2a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c2622a2a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c39aaa1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c39aaa1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c39aaa1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c39aaa1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb800 
PROCEEDINGS: PLAINTIFF CEDARS-SINAI MEDICAL CENTER\rquote S MOTION FOR PARTIAL SUMMARY JUDGMENT OF INFRINGEMENT [251]
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c39aaa1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c39aaa1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DEFENDANTS\rquote  CORRECTED MOTION FOR SUMMARY JUDGMENT OF PATENT INVALIDITY UNDER 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
 (SUBJECT MATTER INELIGIBILITY) [262]
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c39aaa1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c39aaa1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DEFENDANTS\rquote  CORRECTED MOTION FOR SUMMARY JUDGMENT OF PATENT INVALIDITY UNDER 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb600 
 U.S.C. \u167\'3f 112 (NONENABLEMENT) [263]
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Honorable 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0151975701&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
GEORGE H. WU
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, UNITED STATES DISTRICT JUDGE
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
The Court\rquote s Tentative Ruling is circulated and attached hereto. Defendants\rquote  Motions are TAKEN UNDER SUBMISSION. Court to issue ruling.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Tentative Ruling on (1) Defendant\rquote s Motion for Summary Judgment as to Patent Invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, (2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Defendant\rquote s Motion for Summary Judgment as to Patent Invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, and (3) Plaintiff\rquote s Motion for Partial Summary Judgment as to Patent Infringement
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c3ae321a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c3ae321a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c3ae321a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c3ae321a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Introduction
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_1_15}{\*\bkmkend co_pp_sp_999_1_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Plaintiff Cedars-Sinai brings this action against Defendants Quest Diagnostics, Inc. and Quest Diagnostics Nichols Institute (collectively, \u8220\'3fQuest\u8221\'3f) alleging various claims, including for trade secret misappropriation, breach of contract, and patent infringement. Docket No. 1; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Docket No. 23 (Second Amended Complaint, \u8220\'3fSAC\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In November 2017, Quest moved to dismiss the SAC, arguing among other things that Cedars-Sinai\rquote s claim for infringement of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 9,702,884 (\u8220\'3fthe \lquote 884 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 must be dismissed because the asserted claims are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Docket No. 26. The Court ultimately found that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were directed to an abstract idea, but concluded that \u8220\'3fexpedited claim construction and expedited claim construction discovery as to the claim term \u8216\'3fan assay\u8217\'3f would be beneficial before the Court reache[d] a determination as to patentability under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Docket No. 51 at 17. In claim construction proceedings for the term \u8220\'3fassay,\u8221\'3f the Court rejected Quest\rquote s arguments that the term should be limited to a manufactured, vinculin-based assay and did not construe the term. Docket No. 80 at 12-13, 14. In a telephonic status conference with the parties after claim construction proceedings, the Court indicated that, particularly in light of other disputes identified by Cedars-Sinai during claim construction, Quest would need to fully renew its 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 challenge rather than presenting an abridged offer of proof. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Docket No. 81 (lifting stay in action and setting remaining pretrial dates).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On the deadline for the parties to file motions, Quest filed three summary judgment motions: (1) a Motion for Summary Judgment as to Patent Invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Docket No. 262 (public); Docket No. 268 (sealed)); (2) a Motion for Summary Judgment as to Patent Invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Non-Enablement) (Docket No. 263 (public); Docket No. 269 (sealed)); and (3) a Motion for Summary Judgment as to Cedars-Sinai\rquote s Trade Secret and Breach of Contract Claims (Docket No. 258 (public); Docket No. 270 (sealed)).
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Cedars-Sinai filed a Motion for Partial Summary Judgment as to Patent Infringement. Docket No. 251.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This tentative ruling addresses the pending summary judgment motions related to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012051097030_ID0EXJAC_15}{\*\bkmkend co_fnRef_B00012051097030_ID0EXJAC_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012051097030_15" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Quest\rquote s invalidity motions have been fully briefed.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022051097030_ID0EBKAC_15}{\*\bkmkend co_fnRef_B00022051097030_ID0EBKAC_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022051097030_15" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In response to Cedars-Sinai\rquote s infringement motion, Quest filed a Statement of Non-Opposition. Docket No. 275. In the Statement, Quest \u8220\'3fdoes not contest\u8221\'3f that its IBSDetex test meets all limitations of asserted Claims 3 and 4 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1. Quest, however \u8220\'3fmaintain[s] its position that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims 3 and 4 (as well as asserted claims 9 and 10) are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS102&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
102
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS103&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Cedars-Sinai responds to Quest\rquote s statement by maintaining its position that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are not invalid. Docket No. 291.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_2_15}{\*\bkmkend co_pp_sp_999_2_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*2
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For the reasons stated in this Order, the Court would find that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are drawn to patent-ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and would 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
GRANT
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Quest\rquote s Motion for Summary Judgment of Invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court would thus also 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DENY
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 both Quest\rquote s Motion for Summary Judgment of Invalidity under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and Cedars-Sinai\rquote s Motion for Summary Judgment of Partial Patent Infringement as 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
MOOT.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c403a51a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c403a51a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c403a51a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c403a51a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
II. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Undisputed Facts
}
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032051097030_ID0E2CAE_15}{\*\bkmkend co_fnRef_B00032051097030_ID0E2CAE_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032051097030_15" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued July 11, 2017 and is titled \u8220\'3fMethods for Detecting the Presence of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Irritable Bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Syndrome and System for Diagnosing Same.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Statement of Genuine Disputes of Material Fact re 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Motion (Sealed) (\u8220\'3fSDF\u8221\'3f), Docket No. 300-1 \u182\'3f 6. Cedars-Sinai alleges that Quest infringes Claims 3, 4, 9, and 10 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAsserted Claims\u8221\'3f). SDF \u182\'3f 1. The four Asserted Claims recite:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
3. A system for diagnosing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 syndrome, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
an isolated biological sample from a subject desiring diagnosis regarding 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 syndrome (IBS); and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an assay for detecting in the biological sample, a level of an anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
4. The system of claim 3, wherein the assay is an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (ELISA), wherein the ELISA comprises using vinculin, SEQ ID NO:1 or a fragment thereof as a substrate or reagent to bind the anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
9. A system, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
an isolated biological sample from a subject desiring a diagnosis to distinguish between 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 syndrome (IBS) and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic33f4532475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
inflammatory bowel disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (IBD); and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
an assay for detecting in the biological sample, a level of anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
10. The system of claim 9, wherein the assay is an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (ELISA), wherein the ELISA comprises using vinculin, SEQ ID NO:1 or a fragment thereof as a substrate or reagent to bind the anti-vinculin antibody.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fThe correlation between anti-vinculin antibodies is a natural phenomenon and is not due to any human intervention.\u8221\'3f SDF \u182\'3f 16. \u8220\'3fAs of the filing of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, vinculin and anti-vinculin antibodies were commercially available.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 23. Also as of the filing of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fordinary skilled artisans would have generally appreciated the use of assays, such as ELISA.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 28. ELISA was first developed in the 1970s and was \u8220\'3freported to be \u8216\'3fone of the most widely used biochemical methods in laboratory analysis and diagnostics.\u8217\'3f \u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f\u182\'3f 30-31. ELISA has long been used to detect levels of antibodies. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 34. Beyond disclosing examples using a particular reagent for ELISA, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 specification itself does not disclose any particular methodologies for using ELISA that were new or different from what was already known in the art.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042051097030_ID0EFMAE_15}{\*\bkmkend co_fnRef_B00042051097030_ID0EFMAE_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042051097030_15" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u182\'3f 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states, \u8220\'3f[o]ne of ordinary skill in the art will readily appreciate methods and systems that can be used to detect the presence or absence of an antibody that binds specifically to vinculin, SEQ ID NO: 1 or a fragment thereof. These methods and systems include but are not limited to ELISA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad314d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunohistochemistry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iaf7c5e9d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fluorescence in situ hybridization
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (FISH), radioimmuno assays, and affinity purification.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 12:28-36.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c46f111a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c46f111a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c46f111a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c46f111a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
III. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Legal Standards
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c46f111a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c46f111a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
A. Summary Judgment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_3_15}{\*\bkmkend co_pp_sp_999_3_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*3
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Summary judgment shall be granted when a movant \u8220\'3fshows that there is no genuine issue as to any material fact and that the movant is entitled to judgment as a matter of law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Fed. R. Civ. P. 56(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007701262&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_860&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_860" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Miranda v. City of Cornelius
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 429 F.3d 858, 860 n.1 (9th Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As to materiality, \u8220\'3f[o]nly disputes over facts that might affect the outcome of the suit under the governing law will properly preclude the entry of summary judgment.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132674&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_248&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_248" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson v. Liberty Lobby, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 477 U.S. 242, 248 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A dispute as to a material fact is \u8220\'3fgenuine\u8221\'3f if there is sufficient evidence for a reasonable jury to return a verdict for the nonmoving party. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
To satisfy its burden at summary judgment, a moving party without the burden of persuasion \u8220\'3fmust either produce evidence negating an essential element of the nonmoving party\rquote s claim or defense or show that the nonmoving party does not have enough evidence of an essential element to carry its ultimate burden of persuasion at trial.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000111545&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1102&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1102" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nissan Fire & Marine Ins. Co. v. Fritz Cos., Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 210 F.3d 1099, 1102 (9th Cir. 2000)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2001753324&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1076&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1076" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Devereaux v. Abbey
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 263 F.3d 1070, 1076 (9th Cir. 2001)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
en banc
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000302582&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_532&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_532" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Fairbank v. Wunderman Cato Johnson
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 212 F.3d 528, 532 (9th Cir. 2000)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
If the party moving for summary judgment meets its initial burden of identifying for the court the portions of the materials on file that it believes demonstrate the absence of any genuine issue of material fact, the nonmoving party may not rely on the mere allegations in the pleadings in order to preclude summary judgment[, but instead] must set forth, by affidavit or as otherwise provided in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000600&cite=USFRCPR56&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Rule 56
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, specific facts showing that there is a genuine issue for trial.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1987015303&pubNum=0000350&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_350_630&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_630" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
T.W. Elec. Serv., Inc., v. Pac. Elec. Contractors Ass\rquote n
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 809 F.2d 626, 630 (9th Cir. 1987)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (internal citations and quotation marks omitted). In judging evidence at the summary judgment stage, the court does not make credibility determinations or weigh conflicting evidence, and views all evidence and draws all inferences in the light most favorable to the non-moving party. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1987015303&pubNum=0000350&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_350_630&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_630" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 630-31
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986115992&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Matsushita Elec. Indus. Co. v. Zenith Radio Corp.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 475 U.S. 574 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2024496948&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Hrdlicka v. Reniff
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 631 F.3d 1044 (9th Cir. 2011)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2007985657&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1075&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1075" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Motley v. Parks
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 432 F.3d 1072, 1075 n.1 (9th Cir. 2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
en banc
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The initial burden is on the moving party to demonstrate an absence of a genuine issue of material fact or to demonstrate that the nonmoving party will be unable to make a sufficient showing on an essential element of its case for which it has the burden of proof. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132677&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_323&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_323" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Celotex Corp. v. Catrett
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 477 U.S. 317, 323 (1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Only if the moving party meets its burden must the non-moving party produce evidence to rebut the moving party\rquote s claim and create a genuine issue of material fact. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986132677&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_322&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_322" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 322-23
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the non-moving party meets this burden, then the motion will be denied. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2000111545&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1103&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1103" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Nissan Fire & Marine Ins. Co.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 210 F.3d at 1103
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c4b5de1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c4b5de1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c4b5de1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c4b5de1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
B. Patent Eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
\sb200 
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
An invention or a discovery is patentable if it is a 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3fnew and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fIn choosing such expansive terms ... Congress plainly contemplated that the patent laws would be given wide scope.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1980116775&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_308&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_308" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Chakrabarty
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 447 U.S. 303, 308 (1980)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Still, the Supreme Court has identified exceptions to this wide scope to \u8220\'3fdistinguish patents that claim the building blocks of human ingenuity, which are ineligible for patent protection, from those that integrate the building blocks into something more.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_708_2350&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2350" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. Ltd. v. CLS Bank Int\rquote l
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. 2347, 2350 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_89&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_89" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 89 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
) (internal quotations omitted). These exceptions to patent protection are \u8220\'3flaws of nature, natural phenomena, and abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_185&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_185" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 185 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While the boundaries of the judicial exceptions remain subject to further development, the Supreme Court has clearly stated the policy underlying those exceptions: avoiding patents that \u8220\'3ftoo broadly preempt the use of a natural law [or abstract idea].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_708_1294&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1294" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1294
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, patent law should \u8220\'3fnot inhibit further discovery by improperly tying up the future use of laws of nature [or abstract ideas].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_4_15}{\*\bkmkend co_pp_sp_999_4_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*4
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court \u8220\'3fset forth a framework for distinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The first step is to ask \u8220\'3fwhether the claims at issue are directed to one of those patent-ineligible concepts.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 If not, the claims fall within the scope of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and are patent-eligible. If the claims are directed to one of the exceptions, the next step is to search for an \u8220\'3finventive concept\u8221\'3f that is \u8220\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the natural law itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72-73
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In doing so, a court must \u8220\'3fconsider the elements of each claim both individually and \u8216\'3fas an ordered combination\u8217\'3f to determine whether the additional elements \u8216\'3ftransform the nature of the claim\u8217\'3f into a patent-eligible application.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 134 S. Ct. at 2355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_78" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 78-79
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The question in the law of nature context is whether the claims at issue add more than \u8220\'3f \u8216\'3fwell-understood, routine, conventional activity already engaged in by the scientific community\u8217\'3f \u8221\'3f to the law of nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1047&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1047" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1047 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_79&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_79" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 79-80
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). \u8220\'3f[G]roundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_577&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_577" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ass\rquote n for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 577 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c4f5581a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c4f5581a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c4f5581a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c4f5581a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
IV. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Discussion
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4c4f5581a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4c4f5581a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A. 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 Step One
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court previously concluded that the Asserted Claims are drawn to an abstract idea under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One. The Court\rquote s prior analysis and conclusion is incorporated by this referenced. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Docket No. 51 as 12-16. For convenience, part of the Court\rquote s analysis is repeated here:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Quest argues that the Asserted Claims are invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they \u8220\'3fare directed to a single natural phenomenon: the correlation between the presence of anti-vinculin antibodies and IBS.\u8221\'3f Motion at 17. Quest argues, \u8220\'3f[t]he Federal Circuit has found substantively identical claims invalid under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 19 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1361&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1361" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics, LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d 1352, 1361 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Quest also argues that the Asserted Claims represent a \u8220\'3fsweeping preemption of the natural phenomenon,\u8221\'3f as Claims 3 and 9 \u8220\'3fpreempt all means for detecting the natural phenomenon of elevated vinculin in IBS patients.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 20. Quest argues that Claims 4 and 10 fare no better because \u8220\'3fthe recitation of ELISA to detect anti-vinculin is not sufficiently novel or specific to transform the natural phenomenon into a patent eligible application thereof.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb200 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars-Sinai argues that Quest fails to prove invalidity of the Asserted Claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Opp\rquote n at 14. Cedars-Sinai first asserts that a person of ordinary skill in the art would understand the term \u8220\'3fan assay\u8221\'3f as used in the claims to mean \u8220\'3fa vinculin-based assay.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 15-16. Cedars-Sinai further contends that, \u8220\'3f[b]ecause vinculin is an intracellular protein, it must first be 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
manufactured
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and isolated in order to prepare the vinculin-based assay of the asserted claims.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 19 (emphasis in original). Cedars-Sinai asserts that \u8220\'3fvinculin utilized in the claimed assay will have different characteristics and will behave differently in the environment of a diagnostic assay than naturally-occurring vinculin would within the cellular environment.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 20. Based on these characterizations, Cedars-Sinai argues the Asserted Claims \u8220\'3fcannot be directed to natural phenomena because they each use a non-naturally occurring component: vinculin.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 21. Cedars-Sinai argues that preemption is not a concern because the Asserted Claims are \u8220\'3flimited specifically to vinculin-based assays.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 at 22.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In reply, Quest again emphasizes the Federal Circuit\rquote s decision in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Reply at 12. Quest argues the Asserted Claims are invalid even accepting Cedars-Sinai\rquote s construction of \u8220\'3fan assay\u8221\'3f as \u8220\'3fa vinculin-based assay.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 15-16. Quest again compares the Asserted Claims to the claims at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and notes that even though the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims implicated manufactured components in commercially-available tests, the claims were still patent-ineligible because the focus of the claims was detecting MPO levels in the body using known techniques. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 17. Quest argues that even assuming Cedars-Sinai\rquote s construction of \u8220\'3fan assay,\u8221\'3f the preemption analysis does not change because, as Cedars-Sinai represented in its opposition, an assay for detecting a level of anti-vinculin antibody \u8220\'3fmust necessarily use vinculin as the assay reagent.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 at 18 (quoting Opp\rquote n at 16).
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_5_15}{\*\bkmkend co_pp_sp_999_5_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*5
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 In analyzing the Asserted Claims, it is helpful to consider and compare other claims that have been tested against 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1334&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1334" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1334 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe Supreme Court has not established a definitive rule to determine what constitutes an \u8216\'3fabstract idea\u8217\'3f sufficient to satisfy the first step of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 inquiry. Rather, both this court and the Supreme Court have found it sufficient to compare claims at issue to those claims already found to be directed to an abstract idea in previous cases.\u8221\'3f (internal citations omitted).)
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Federal Circuit affirmed a district court\rquote s determination that claims from three patents were invalid because they were not directed to patent-eligible subject matter. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1355" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d at 1355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Federal Circuit specifically concluded that the claims were \u8220\'3fdirected to multistep methods for observing the law of nature that MPO [ (myeloperoxidase) ] correlates to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ibd1c122b475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cardiovascular disease
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1360&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1360" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1360
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. One of the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 patent claims, for instance, recited:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
21. A method of assessing the risk of requiring medical intervention in a patient who is presenting with chest pain, comprising
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
characterizing the levels of myeloperoxidase activity, myeloperoxidase mass, or both, respectively in the bodily sample from the human patient, wherein said bodily sample is blood or a blood derivative,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a patient whose levels of myeloperoxidase activity, myeloperoxidase mass, or both is characterized as being elevated in comparison to levels of myeloperoxidase activity, myeloperoxidase mass or both in a comparable bodily samples obtained from individuals in a control population is at risk of requiring medical intervention to prevent the occurrence of an adverse cardiac event within the next six months.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1356-57 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2017572769&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=I86f818b8c15511ddbc7bf97f340af743&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 7,459,286
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Other dependent claims of the same patent limited myeloperoxidase (\u8220\'3fMPO\u8221\'3f) detection \u8220\'3fby flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and further require[d] detection of another compound, troponin.\u8221\'3f In concluding particular independent patent claims were representative, the Federal Circuit noted that the dependent claims in the three patents \u8220\'3fmerely recite[d] known methods of detecting MPO or MPO derivatives and applie[d] the correlation between these biomarkers and cardiovascular health.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1360. The Federal Circuit noted that the plaintiff \u8220\'3fhas not created a new laboratory technique; rather, it uses well-known techniques to execute the claimed method. The specification of the testing patents confirm that known testing methods could be used to detect MPO, and that there were commercially available testing kits for MPO detection.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 at 1361.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Asserted Claims in this matter appear initially to be highly analogous to the claims invalidated by the Federal Circuit in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 The Asserted Claims essentially recite the combination of an assay for detecting an anti-vinculin antibody and a biological sample \u8220\'3ffrom a subject desiring diagnosis\u8221\'3f of IBS. The crux of the claims thus relies on the fact that there is a correlation between IBS and a subject\rquote s levels of anti-vinculin antibody. In other words, the claims are directed to systems for observing the law of nature that anti-vinculin antibody correlates to IBS.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This conclusion at 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice/Mayo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step 1 is not impacted by Cedars-Sinai\rquote s argument that the claim phrase \u8220\'3fan assay\u8221\'3f in the Asserted Claims must be construed as \u8220\'3fa vinculin-based assay.\u8221\'3f Assuming the claim term \u8220\'3fan assay\u8221\'3f means \u8220\'3fa vinculin-based assay,\u8221\'3f and even further assuming the claimed vinculin-based assay utilizes manufactured or non-naturally-occurring vinculin, does not change the analysis. The focus of the Asserted Claims is not on the assay itself, but on the system\rquote s goal of diagnosing IBS. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Claim 3 (\u8220\'3fA system for diagnosing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ee0a9e475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
irritable bowel
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 syndrome, comprising ...\u8221\'3f). Whether the system can diagnose IBS, in turn, is dependent on the correlation between IBS and anti-vinculin antibody. This core law of nature persists even where the claimed diagnostic assay is a vinculin-based assay. Cedars-Sinai attempts to distinguish 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and other cases on the basis that the Asserted Claims \u8220\'3fprovide a vinculin-based assay that utilizes ... non-naturally occurring components, and the subject vinculin and anti-vinculin antibody were not known or expected to be predictive of IBS in assays.\u8221\'3f Opp\rquote n at 22-23 n.8. But this argument is an exercise in misdirection. Like the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims, the Asserted Claims \u8220\'3fpurport[ ] to detect naturally-occurring [anti-vinculin antibodies] through well-known techniques based on a known correlation between [anti-vinculin antibodies] and the disease state.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (Cedars-Sinai\rquote s parenthetical describing patents at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2041877586&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1362&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1362" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 859 F.3d at 1362
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fCleveland Clinic does not purport to have invented colorimetric-based assay, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, or ELISA, or any of the claimed methods to \u8216\'3fsee\u8217\'3f MPO and its derivatives in bodily samples. Rather, the claims here instruct that MPO levels be detected or determined using any of these known techniques.\u8221\'3f). Specifically, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 states, \u8220\'3f[o]ne of ordinary skill in the art will readily appreciate methods and systems that can be used to detect the presence or absence of an antibody that binds specifically to vinculin, SEQ ID NO: 1 or a fragment thereof. These methods and systems include but are not limited to ELISA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad314d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunohistochemistry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iaf7c5e9d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fluorescence in situ hybridization
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (FISH), radioimmuno assays, and affinity purification.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 at 12:28-36.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_6_15}{\*\bkmkend co_pp_sp_999_6_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*6
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The fact that the correlation between vinculin and IBS was not known before Cedars-Sinai\rquote s discovery is also irrelevant. As a law of nature, this correlation has always existed. Simply because Cedars-Sinai was the first to discover it, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, make a \u8220\'3fbreakthrough\u8221\'3f in the field, does not change its inherent character as a law of nature. For this reason, any attempt by Cedars-Sinai to distinguish 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 based on the argument that the correlation between MPO and cardiovascular health was already known before 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic\rquote s
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patent issued is also unpersuasive. As stated, \u8220\'3fgroundbreaking, innovative, or even brilliant discovery does not by itself satisfy the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_577&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_577" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad Genetics
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 577
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, the Asserted Claims are directed to a law of nature under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Step One.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Importantly, as Quest noted in its reply, Cedars-Sinai has represented that \u8220\'3f \u8216\'3fan assay for detecting ... a level of anti-vinculin antibody\u8217\'3f must necessarily use vinculin as the assay reagent.\u8221\'3f Opp\rquote n at 16; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Reply at 18. If Cedars-Sinai\rquote s position is accepted, under Cedars-Sinai\rquote s own interpretation of the claims, any assay relying on detecting anti-vinculin antibodies in order to diagnose IBS would be covered by the claims. In other words, the Asserted Claims, and particularly Claims 3 and 9, would preempt all assays detecting a correlation between anti-vinculin antibody and IBS. Such sweeping preemption concerns confirm the nature of the Asserted Claims. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_708_1301&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_1301" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 132 S. Ct. at 1301
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (patent law should \u8220\'3fnot inhibit further discovery by improperly tying up the future use of laws of nature.\u8221\'3f). At the first hearing on the Motion, counsel for Cedars-Sinai argued that preemption is not a concern because while the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 covers vinculin-based assays, it does not cover using CdtB assays to diagnose vinculin. As counsel for Quest correctly noted, however, the question of preemption asks whether a particular law of nature is tied up by the patented invention. Simply pointing to a different law of nature (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the correlation between CdtB and IBS as opposed to the correlation between vinculin and IBS) does not address the issue. At the supplemental hearing on the Motion, Cedars-Sinai shifted its argument and stated that the Asserted Claims do not preempt the correlation between anti-vinculin antibodies and IBS, in part because, according to Cedars-Sinai, manufactured vinculin has only a single, specific amino acid sequence. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars-Sinai\rquote s shifting approach will be addressed in the next section, but it is worth noting that again, if true that manufactured vinculin only has a single, specific amino acid sequence, then preemption would remain a problem as others would still be unable to use any vinculin-based assay (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, the only available type of vinculin-based assay) to diagnose IBS.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court concludes that the claims are directed to a law of nature under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step 1 and thus proceeds to analyze 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 Step 2.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Docket No. 51 at 12-16.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court also notes that after it issued its Final Ruling regarding Quest\rquote s Motion to Dismiss, the Federal Circuit decided 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d 743 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
en banc hr\rquote g denied
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2048622456&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
927 F.3d 1333 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 will be discussed in further detail in the next section of this Order, but the Court finds that it also further supports the Court\rquote s determination at 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_751&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_751" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 751
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047911688&pubNum=0006538&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_6538_1017&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_1017" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 760 F. App\rquote x 1013, 1017 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars-Sinai relies on portions of the Federal Circuit\rquote s decision in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to argue that the question of whether claimed components are routine, conventional, and well-understood \u8211\'3f and thus the introduction of potential questions of material fact \u8211\'3f should now be addressed under both 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One and Step Two. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fAs in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariosa
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we conclude that claims 7-9 are directed to a natural law because the claimed advance was only in the discovery of a natural law, and that the additional recited steps only apply conventional techniques to detect that natural law. The specification of the \lquote 820 patent highlights the discovery of the natural law ... Further, the specification describes the claimed concrete steps for observing the natural law as conventional.\u8221\'3f); Docket No. 288 at 6-10. Although the Court agrees that certain statements in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 could initially be read to conflate the two 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 steps, the Court ultimately is not persuaded by Cedars-Sinai\rquote s interpretation of 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Other language in the opinion, as well as a plethora of other Federal Circuit cases, continue to reserve the potential fact question of whether components are routine, conventional, and well-understood for 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_750&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_750" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 750
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe step one \u8220\'3fdirected to\u8221\'3f inquiry focuses on the claim as a whole. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
E.g.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039474697&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1353&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1353" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Elec. Power Grp., LLC v. Alstom S.A.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 830 F.3d 1350, 1353 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. To determine whether a claim is directed to an ineligible concept, we have frequently considered whether the claimed advance improves upon a technological process or merely an ineligible concept, based on both the written description and the claims.\u8221\'3f). Moreover, particularly in the circumstances presented by this case, the Court does not see a relevant distinction between conducting the inventive concept analysis now or in the next step. For these reasons, although the Court acknowledges there is some overlap in the two steps of the test, the Court declines Cedars-Sinai\rquote s request to affirmatively advance the inventive concept analysis to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One and proceeds to conduct it in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4ca31ad1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4ca31ad1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4ca31ad1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4ca31ad1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
B. 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
 Step Two
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_7_15}{\*\bkmkend co_pp_sp_999_7_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*7
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Final Ruling on the motion to dismiss did not resolve the question of whether the Asserted Claims included an inventive concept under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two. Instead, it deferred until the completion of some additional proceedings. It also noted some of Cedars-Sinai\rquote s arguments at this step, including that: (1) vinculin-based assays were purportedly not well-understood, routine, or conventional at the time of filing of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and (2) that the determination in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is distinguishable because the MPO testing kits covered by the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims were available on the market before the patent was filed. Docket No. 51 at 16-17.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In opposing Quest\rquote s 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 summary judgment motion, Cedars-Sinai again frames the issue as whether \u8220\'3fanti-vinculin assays were well-known, routine, and conventional at the time of the invention.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Docket No. 288 at 13. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, however, is instructive in this regard. The patent at issue in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 involved 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic2cd21d2475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
myasthenia gravis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fMG\u8221\'3f), a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic6c75a40475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
neurological disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_747&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_747" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d at 747
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The named inventors of the patent discovered that about 20% of MG patients, instead of generating a known type of autoantibody, generated autoantibodies to a membrane protein called MuSK. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Some relevant claims of the patent recited:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
1. A method for diagnosing neurotransmission or developmental disorders related to [MuSK] in a mammal comprising the step of detecting in a bodily fluid of said mammal autoantibodies to an epitope of [MuSK].
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
* * *
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
7. A method according to claim 1, comprising contacting MuSK or an epitope or antigenic determinant thereof having a suitable label thereon, with said bodily fluid, immunoprecipitating any antibody/MuSK complex or antibody/MuSK epitope or antigenic determinant complex from said bodily fluid and monitoring for said label on any of said antibody/MuSK complex or antibody/MuSK epitope or antigen determinant complex, wherein the presence of said label is indicative of said mammal is suffering from said neurotransmission or developmental disorder related to [MuSK].
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 At 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step One, the majority found the claims directed to natural law, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the correlation between MG and MuSK. At 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two, the patent holder in 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 presented a similar argument to the one Cedars-Sinai makes here. Namely, the patent holder argued that \u8220\'3fthe claimed steps were unconventional because they had not been applied to detect MuSK autoantibodies prior to Athena\rquote s discovery of the correlation between MuSK autoantibodies and MG.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 754. The Federal Circuit rejected this argument, stating:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Even accepting that fact, we cannot hold that performing standard techniques in a standard way to observe a newly discovered natural law provides an inventive concept. This is because \u8220\'3f[t]he inventive concept necessary at step two ... cannot be furnished by the unpatentable law of nature ... itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038639328&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_1376&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1376" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Genetic Techs. Ltd. v. Merial L.L.C.
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 818 F.3d 1369, 1376 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_73&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_73" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 73, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 (considering whether the \u8220\'3fclaimed processes (apart from the natural laws themselves)\u8221\'3f were routine and conventional). Rather, to supply an inventive concept the sequence of claimed steps must do more than adapt a conventional assay to a newly discovered natural law; it must represent an inventive application beyond the discovery of the natural law itself. Because claims 7-9 fail to recite such an application, they do not provide an inventive concept.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although Cedars-Sinai argues that scientific assays involving vinculin and/or anti-vinculin antibodies have not been proven to be routine, conventional, or well-understood, Cedars-Sinai does not otherwise reasonably argue that the assay techniques themselves rely on unconventional aspects. Indeed, the Asserted Claims simply refer to either \u8220\'3fan assay for detecting ... a level of an anti-vinculin antibody\u8221\'3f or \u8220\'3fan 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic7562c94475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
enzyme-linked immunosorbent assay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (ELISA), wherein the ELISA comprises using vinculin, SEQ ID NO:1 or a fragment thereof as a substrate or reagent.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Claims 3, 4. There are no special details provided about the assays themselves or any unique techniques required by the Asserted Patents for their execution. Similarly, the patent specification explains that \u8220\'3f[o]ne of ordinary skill in the art 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
will readily appreciate
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 methods and systems that can be used to detect the presence or absence of an antibody that binds specifically to vinculin, SEQ ID NO: 1 or a fragment thereof. These methods and systems include but are not limited to ELISA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad314d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunohistochemistry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, flow 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ic8ad5894475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cytometry
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Iaf7c5e9d475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fluorescence in situ hybridization
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (FISH), radioimmuno assays, and affinity purification.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 12:28-36 (emphasis added). In other words, the patent specification treats the disclosed assays themselves as standard assays, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 routine, conventional, and well-understood. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 SDF \u182\'3f\u182\'3f 28, 30, 31, 34.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_8_15}{\*\bkmkend co_pp_sp_999_8_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 At most, Cedars-Sinai emphasizes the deposition testimony of patent co-inventor Dr. Christopher Chang, who explained that ELISA must be developed and optimized for particular applications for it to work. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Docket No. 288 at 20. But the Court finds that a person of ordinary skill in the art adjusting the requisite parameters of a known assay so that it is successful for a specific application should not lead to the conclusion that the assay in the context of the specific application must then be considered non-routine and unconventional. This is particularly true where the patent specification and claims make no mention of what, if any, adjustments are needed, effectively assuming that they could be effectively implemented by person of skill in the art without requiring further discussion in the patent itself. As 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 noted, the claimed sequence of steps \u8220\'3fmust do more than 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
adapt
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a conventional assay to a newly discovered natural law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_754&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_754" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Athena
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 915 F.3d at 754
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047911688&pubNum=0006538&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_6538_1019&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_6538_1019" }{\fldrslt 
{\b0 \cf20 \f2 \i1 \fs20 
{\b0 \cf20 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Cleveland Clinic Found. v. True Health Diagnostics LLC
}
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 760 F. App\rquote x 1013, 1019 (Fed. Cir. 2019)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
The patents
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 disclose that an 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib5ba9392475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
immunoassay
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was a known technique for measuring protein mass and 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
never suggest that any 
}
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i1 \fs20 \sa0 \sb0 
significant
}
}
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
 adjustments needed to be made
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to accommodate its use for measuring blood MPO levels.\u8221\'3f (emphasis added).). Such, however, would be the result of accepting Cedars-Sinai\rquote s position.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052051097030_ID0EDAAI_15}{\*\bkmkend co_fnRef_B00052051097030_ID0EDAAI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052051097030_15" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Cedars-Sinai\rquote s disputed facts are focused on incorrect characterizations of the law that would rely on the abstract concept itself (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the search for anti-vinculin antibodies using an assay) to demonstrate that the claims are not drawn to routine, conventional, or well-understood components. Once 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two is viewed from the correct legal lens, Cedars-Sinai\rquote s alleged factual disputes cannot create a question of material fact sufficient to support denial of summary judgment. Cedars-Sinai has not otherwise sufficiently argued that the claimed steps, considered individually or as an ordered combination, are drawn to anything other than routine, conventional, and well-understood components, and the Court finds that the Asserted Claims fail to pass muster under 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Step Two.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062051097030_ID0EFEAI_15}{\*\bkmkend co_fnRef_B00062051097030_ID0EFEAI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062051097030_15" }{\fldrslt 
{\super \b0 \cf20 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4caf9df1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4caf9df1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_I4caf9df1a0d411eabb18ab3f21342}{\*\bkmkend co_anchor_I4caf9df1a0d411eabb18ab3f21342}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
V. 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul1 \strike0 \i0 \fs20 \sa0 \sb400 
Conclusion
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_999_9_15}{\*\bkmkend co_pp_sp_999_9_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*9
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 For the reasons stated in this Order, the Court would find that the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 884 Patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are drawn to patent-ineligible subject matter under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and would 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
GRANT
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Quest\rquote s Motion for Summary Judgment of Invalidity Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 
}
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court would thus also 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
DENY
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 both Quest\rquote s Motion for Summary Judgment of Invalidity Under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f2 \i0 \fs20 \chcbpat23 
{\b1 \cf22 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf20 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 112
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and Cedars-Sinai\rquote s Motion for Summary Judgment of Partial Patent Infringement as 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
MOOT.
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_15}{\*\bkmkend co_allCitations_15}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Slip Copy, 2019 WL 8884101
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012051097030_15}{\*\bkmkend co_footnote_B00012051097030_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012051097030_ID0EXJAC_15" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
A separate ruling has been issued concurrently regarding Quest\rquote s summary judgment motion related to the breach of contract and trade secret claims.
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Court granted the parties\rquote  applications to file certain of their briefs and supporting evidence under seal. For the purposes of this tentative ruling, the Court will cite to the sealed versions throughout. To the extent the parties wish to keep certain information in this tentative ruling confidential, they must provide the Court with a proposed redacted version of this ruling within two business days of this hearing.
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022051097030_15}{\*\bkmkend co_footnote_B00022051097030_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022051097030_ID0EBKAC_15" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Opposition to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Motion, Docket No. 278 (public), Docket No. 288 (sealed); Reply to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
101
}
}
}
{\b0 \cf20 \f4 \i0 \fs18 \chcbpat2 
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Motion, Docket No. 295 (public), Docket No. 300 (sealed); Opposition to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 112
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Motion, Docket No. 279 (public), Docket No. 289 (sealed); Reply to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS112&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 112
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Motion, Docket No. 296 (public), Docket No. 301 (sealed).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032051097030_15}{\*\bkmkend co_footnote_B00032051097030_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032051097030_ID0E2CAE_15" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Some of the underlying \u8220\'3fundisputed\u8221\'3f facts cited herein have been disputed by Plaintiff or Defendant. The Court has reviewed said disputes and has included in this summary only facts that are supported by the cited evidence, altering the proffered facts if necessary to accurately reflect the uncontroverted evidence. To the extent that the cited underlying \u8220\'3fundisputed\u8221\'3f facts have been disputed, the Court finds that the stated disputes: (1) fail to controvert the proffered \u8220\'3fundisputed\u8221\'3f facts, (2) dispute the facts on grounds not germane to the below statements, and/or (3) fail to cite evidence in support of the disputing party\rquote s position. As such, the Court treats such facts as undisputed. Any proffered facts not included in this tentative ruling were found to be: (1) improper opinions or conclusions rather than facts, (2) were unsupported by admissible evidence, (3) were deemed irrelevant to the Court\rquote s present analysis, or (4) some combination thereof. To the extent the Court uses any facts in the Discussion section of this tentative ruling, and does not note that they are disputed, it has determined that they are undisputed.
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Neither party submitted evidentiary objections to the other side\rquote s proffered evidence.
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li180 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042051097030_15}{\*\bkmkend co_footnote_B00042051097030_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042051097030_ID0EFMAE_15" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Cedars-Sinai disputes the fact that \u8220\'3f[t]he 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 884 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 does not disclose any particular methodologies for using ELISA that were new or different from what was already in the art\u8221\'3f by stating, \u8220\'3f[t]he 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 884 Patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 discloses the use of a new ELISA with a specific vinculin as the reagent for detecting the level of anti-vinculin antibodies in a biological sample.\u8221\'3f SDF \u182\'3f 
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf1 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 884 Patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, Declaration of Dr. Uwe Christians in Support of Opposition to Motion to Dismiss, Docket No. 
}
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \i0 \fs18 \chcbpat23 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf1 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
-6 \u182\'3f\u182\'3f 26-27).
\par 
}
}
}
}
}\b0 \cf1 \f4 \strike0 \i0 \fs18 \sa0 \sb0 \ri0 \ul0 \qj \li0 \chcbpat2 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052051097030_15}{\*\bkmkend co_footnote_B00052051097030_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052051097030_ID0EDAAI_15" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Court notes that its determinations in this regard are based on its interpretation and understanding of the Federal Circuit\rquote s decision in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, which is binding on it. Quest, however, explicitly states:
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
To be clear, Quest is not arguing that there cannot be an unconventional assay for a biomarker or that there is a 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
per se
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 rule that claims involving a diagnostic assay are always subject matter ineligible. Where patent claims directed to a natural law involving a correlation between a biomarker and a disease expressly recite an unconventional technique for observing or measuring that biomarker, those claims would be patent eligible subject matter under Alice/Mayo Step Two. [Footnote 9: 
}
{\b1 \cf1 \f4 \i0 \fs18 
{\b1 \cf1 \f4 \i1 \fs18 
{\b1 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
In fact, Athena Diagnostics, Inc., a wholly owned subsidiary of Quest, is currently contesting the holding of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Athena Diagnostics, 915 F.3d 743
}\b1 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 }}
{\b1 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
, that the claimed assay was well-understood, routine, and conventional and that the asserted claims were directed to a law of nature
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
.].
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Docket No. 300 at 16, 16 n.9 (emphasis added). The Court notes that based on its reading of 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and other cases, it seems that the current state of the law 
}
{\b1 \cf1 \f4 \i0 \fs18 
{\b1 \cf1 \f4 \i1 \fs18 
{\b1 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
does
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 create a rule that claims involving a 
}
{\b1 \cf1 \f4 \i0 \fs18 
{\b1 \cf1 \f4 \i1 \fs18 
{\b1 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
known
}
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 diagnostic assay applied to a newly-discovered correlation between a biomarker and disease are patent-ineligible, at least where the intrinsic record fails to discuss any technical impediment to using the known diagnostic assay in a standard way to satisfy the claimed steps. However, rather than acknowledging this aspect of 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, Quest asks the Court to determine based on the factual record presented that certain scientific articles support the conclusion that anti-vinculin assays specifically were routine, conventional, and well-understood at the time the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 884 Patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 was filed. The Court declines to do so, and notes that if the analysis were to go so far, it would likely have agreed with Cedars-Sinai that questions of fact regarding the circumstances of those scientific articles would preclude a summary judgment determination.
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062051097030_15}{\*\bkmkend co_footnote_B00062051097030_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062051097030_ID0EFEAI_15" }{\fldrslt 
{\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf20 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The Court notes that even if the Court had accepted Cedars-Sinai\rquote s construction for the term \u8220\'3fassay,\u8221\'3f the claims would likely still be invalid under 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Mayo/Alice
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Step Two. In 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Athena
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, the Court found:
\par 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li180 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Similar to its step one argument, Athena further argues that the claims recite an inventive concept because they use a man-made molecule, 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, labeled MuSK. Athena analogizes its methods involving labeled MuSK to the composition claims involving cDNA held eligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_780_594&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_594" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Association for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 569 U.S. 576, 594-95, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. However, the method claims at issue here are unlike the claims held eligible in 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Myriad
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, which recited a new composition of matter that was not a natural product. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 For the same reasons that we have concluded that attaching a label to MuSK did not make the claims directed to an eligible concept at step one, we conclude that appending labeling techniques to a natural law does not provide an inventive concept where, as here, the specification describes 125I labeling as a standard practice in a well-known assay.
\par 
}
}
}
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2047478333&pubNum=0000506&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=RP&fi=co_pp_sp_506_754&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_754" }{\fldrslt 
{\b0 \cf20 \f4 \i1 \fs18 
{\b0 \cf20 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Athena
}
}
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 915 F.3d at 754-55
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
; 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 SDF \u182\'3f 23 (\u8220\'3fAs of the filing of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2042156618&pubNum=0004074&originatingDoc=I789390f09f2311ea8cb395d22c142a61&refType=PA&docFamilyGuid=Ica4acd10679411e78775d64af116e6d6&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 884 patent
}\b0 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, vinculin and anti-vinculin antibodies were commercially available.\u8221\'3f).
\par 
}
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf27 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf27 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf27 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf27 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf27 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf27 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf27 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf27 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }